Navigation Links
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Date:2/6/2008

NA. There was no evidence of the selection of PSI-6130 resistant virus in any dose cohort during the 2 weeks of dosing.

The preliminary results of a 4 week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin) in 50 treatment-naive patients chronically infected with HCV genotype 1 demonstrated potent short-term antiviral activity. Eighty-five (85%) of patients receiving R7128 1500mg and Pegasys plus Copegus (n=20) achieved undetectable HCV RNA levels following 4 weeks of treatment, or rapid virologic response. The R7128 combination cohorts demonstrated safety and tolerability comparable to placebo with Pegasys plus Copegus.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in thi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche responds to announcement of IDEAL hepatitis C trial results
2. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
5. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
6. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 RB SEO ... cost SEO service for small businesses. , RBSEO Services ... cannot afford costly search engine optimization service. So, the ... small businesses into account. , On being asked ... have introduced this low cost SEO service because many ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy treatments ... several years, Dr. Roy Schmidt and the staff ... scholarship program for veterans who have been diagnosed ... this summer to discuss veterans’ needs ( http://www.prweb.com/releases/2014/06/prweb11954058.htm ... light on the large number of veterans who ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country singer ... diagnosed with the Alzheimer’s, inspired Seniors Guide writers to review ... The movie, out on October 14, 2014, shows a glimpse ... the disease – which inspires a final tour from the ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Continuing to ... Dermatology is expanding with the addition of a new ... Hammond who has provided leading-edge skin care in Grand ... Dermatology. , “As a doctor, my passion is ... Through partnering with Forefront Dermatology, I’m better able to ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team of ... is pleased to report having saved a client $67,100 ... many cases where Hastings and Hastings has tailored its ... greater portion of their settlement or recovery. The firm ... solution for Arizona car accident victims is achievable through ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... Companies, Inc. (NYSE: PRX ) announced today that it ... 3, 2009 at 9:00 am EST to review results for the ... will release results after the market closes on Monday, March 2, ... website at www.parpharm.com .Access to the live webcast can be ...
... say , , WEDNESDAY, Feb. 25 (HealthDay News) -- University of ... that gives chili peppers their fiery flavor, also works to ... Tuesday in the journal PLoS Biology , researchers found ... and heat. , "The receptor acts like a gate to ...
... who have more years of fertility (the time from ... developing Parkinsons disease than women with fewer years, according ... Einstein College of Medicine of Yeshiva University., , These ... to the bodys own, or endogenous, hormones, including estrogen, ...
... One Reform, Medicare for All, Will Solve Crisis and ... largest organization of registered nurses today praised President Obama,s ... Congress Tuesday night, but emphasized that only genuine reform, ... solve the crisis -- and rein in the skyrocketing ...
... scientific data , , WEDNESDAY, Feb. 25 (HealthDay News) -- ... any new drug applications from a Ranbaxy Laboratories plant ... data. , Ranbaxy, based in India, is one of ... States. , "We took this action after it ...
... GURGAON, India, Feb. 25 Ranbaxy has just received ... approved ANDAs from Ranbaxy,s Paonta Sahib facility have been ... "Application Integrity Policy" or "AIP". Ranbaxy will analyze ... in a timely manner.The FDA has said it has ...
Cached Medicine News:Health News:Naturally produced estrogen may protect women from Parkinson's disease 2Health News:Nurses Welcome President's Call for Comprehensive Health Reform 2Health News:FDA Halts New Applications From Indian Drug Maker's Plant 2Health News:Press Statement Issued by Ranbaxy Laboratories Limited 2
... and 8 Suction Catheters With Contro-Vac Valve ... for Low-Risk Respiratory Suctioning, ,Medline's 6 ... and DeLee Tips are the optimal tools ... utilizes a forward placed suction valve to ...
... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
... Tri-Flo® suction catheter design was created ... patients while still providing high suctioning ... (5/6, 8 or 10 Fr) feature ... catheter placement. Our complete catheter line ...
Tracheal Suction Latex Rubber Catheters - DeLee Tip...
Medicine Products: